Richmond Pharmacology will be attending the 5th Annual Cardiovascular Risk Assessment Summit taking place 26th to 27th January 2011 in Alexandria, Virginia.

Posted:
11
January 2011

Richmond Pharmacology will be attending the 5th Annual Cardiovascular Risk Assessment Summit taking place 26th to 27th January 2011 in Alexandria, Virginia.Cardiovascular toxicities and related adverse events continue to be one of the leading reasons why drugs are stopped in development and approved drugs are withdrawn from the market. Regulatory authorities have developed detailed guidelines on the importance of cardiac safety testing in the preclinical as well as in the clinical setting prior to market approval. This increased scrutiny of cardiac safety issues and the effect of regulations on the development process have made cardiac safety a top priority for pharmaceutical companies.2011 Program Highlights:

  • Hear an FDA Address on the analysis and interpretation of increases in blood pressure and heart rate
  • Learn results of the ICH meeting on ICH E14 requirements
  • Understand integrative preclinical and clinical perspectives on assessing adverse CV events
  • Improve precision, accuracy and predictive value of early clinical assessment
  • Discuss principal requirements of separating drug-induced and heart-rate-induced ECG changes
  • Hear an overview of novel electrophysiological biomarkers that can be used to predict proarrhythmic risk
  • Discuss serum and imaging biomarkers and their potential relevance in drug development
  • Assess the preclinical correlation of troponin elevation and myocardial injury

Dr J�rg T�ubel, medical practitioner and CEO of Richmond Pharmacology, will be hosting a speaker session scheduled for Day 2 of the conference at 08h50 on �What is New in the Design and Clinical Best Practice of TQT Studies�:Between 2006 and 2009 the FDA has reviewed 165 TQT studies performed since the adoption of ICH E14 guideline in 2005. In May 2010 they reported that 22 of those studies were rejected as inconclusive. There have been a large number of publications of TQT studies and this offers the opportunity to review the most effective approach to conduct definitive TQT studies.

  • Appraisal of the various studies published discussing which designs and processes yield best results
  • Proposals for high quality ECG acquisition and analysis
  • Proposals for alternative methods to assess assay sensitivity in TQT Studies

View full meeting programme: click here

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more